Warning Letter — Asanuma Corporation - Sagamihara Factory
The FDA issued a Warning Letter to Asanuma Corporation - Sagamihara Factory following an inspection by the Center for Drug Evaluation and Research (CDER). Although the specific violations are not detailed in this excerpt, the issuance indicates significant deviations from Current Good Manufacturing Practice (CGMP) regulations.
This affects Asanuma Corporation - Sagamihara Factory, its quality management personnel, and any downstream partners or distributors utilizing products manufactured at this site.
The involvement of CDER suggests that the facility may be involved in drug manufacturing or processing. A Warning Letter is a formal notification that can lead to import alerts, withholding of product approvals, or further enforcement actions if the underlying CGMP deficiencies are not remediated to the agency's satisfaction. This signals a need for a comprehensive review of the site's Quality Management System.
Regulatory and Quality teams should verify that foreign manufacturing sites maintain CGMP compliance according to CDER standards. Firms should prepare for increased scrutiny of international manufacturing facilities and ensure all quality management systems are robust prior to FDA inspection.
FDA Warning Letter issued to: Asanuma Corporation - Sagamihara Factory. 06/02/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/asanuma-corporation-721136-sagamihara-factory
Open in openFDA / FDA.gov